Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.38 |
| ▸ | PRKDC | P78527 | 8/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.38 |
| ▸ | ABL1 | P00519 | 3/20 | 0.38 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | HCK | P08631 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471997 | 0.83 | GRM2 (0.34) | SRCEGFRKDRADORA2AADORA1 | |
| SCHEMBL4139840 | 0.83 | ALDH1A1 (0.38) | ADORA2AADORA1MAPK11MAPK14 | |
| SCHEMBL5476722 | 0.75 | GLS (0.31) | — | |
| SCHEMBL4145541 | 0.75 | HSP90AA1 (0.32) | — | |
| SCHEMBL4150397 | 0.75 | SRC (0.40) | SRCPIK3CDPRKDCPIK3CAPIK3CB | |
| SCHEMBL4137276 | 0.71 | SRC (0.37) | SRCPIK3CDPRKDCPIK3CAPIK3CB | |
| SCHEMBL4140232 | 0.71 | SRC (0.42) | SRCPIK3CDPRKDCPIK3CAPIK3CB | |
| SCHEMBL2869270 | 0.71 | PIK3CD (0.44) | SRCPIK3CDPRKDCPIK3CAPIK3CB | |
| SCHEMBL4159884 | 0.70 | PIK3CD (0.38) | SRCPIK3CDPRKDCPIK3CAPIK3CB | |
| SCHEMBL2861359 | 0.69 | SRC (0.40) | SRCPIK3CDPRKDCPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | CNKSR1, NR3C2, CSNK2B | SRC 139/4885PIK3CD 2971/4885PRKDC 1244/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | SRC 151/4885PIK3CD 3161/4885PRKDC 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.